Resources Repository
-
ReviewPublication 2006Ethical Issues in Resource Allocation, Research, and New Product Development
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care …
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care are most acute when needs are great and resources few. This chapter from the Disease Control Priorities in Developing Countries 2nd edition addresses some of these concerns, identifying some of the principal ethical issues that arise in the development and allocation of effective interventions for developing countries and discussing some alternative resolutions. Resource allocation in health and elsewhere should satisfy two main…
Health/Medicine | Government/Law | Preferences/Values | Priority Setting/Ethics | Cost-Effectiveness Analysis | Culture/Society | Science/Technology -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Health/Medicine | Government/Law | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Technology Assessment | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | North America -
ReviewPublication 1982Decision Analysis: An Overview
This article, written for the non-decision analyst, describes what decision analysis is, what it can …
This article, written for the non-decision analyst, describes what decision analysis is, what it can and cannot do, why one should care to do this, and how one does it. Keeney describes decision analysis as "a formalization of common sense for decision problems which are too complex for informal use of common sense." He provides a more technical definition also, describing decision analysis as "a philosophy, articulated by a set of logical axioms, and a methodology…
Health/Medicine | Government/Law | Decision Theory | Preferences/Values | Decision Analysis | Policy/Regulation | Business/Industry | Economics/Finance | Energy/Engineering | Military/Defense | Science/Technology -
ArticlePublication 2024GBD Study 2021 Estimates: Implications for Health Policy & Research
The article discusses findings from the Global Burden of Diseases, Injuries, and Risk Factors Study …
The article discusses findings from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet, which presents estimates of disease burden worldwide from 1990 to 2021. Despite an overall increase in global disability-adjusted life years (DALYs), age-standardized rates have decreased, particularly for communicable diseases like HIV/AIDS and diarrheal diseases. Post-COVID-19 impacts, including long COVID, are highlighted. GBD aids in tracking progress towards global health goals but its iterative nature…
Health/Medicine | Health Outcomes | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Health/Medicine | Cost-Effectiveness Analysis | Chronic Disease/Risk | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Extended Cost-Effectiveness Analysis
Health policies are intended to increase the uptake of effective and efficient interventions and result …
Health policies are intended to increase the uptake of effective and efficient interventions and result in health gains (e.g., premature mortality and morbidity averted). Health policies can also provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, social and health insurance programs can prevent illness-related impoverishment and provide financial risk protection. Health policies can also improve the distribution of health in the population and promote health…
Health/Medicine | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Policy/Regulation | Culture/Society | Economics/Finance | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2024Hepatitis C Elimination in Rwanda: Progress, Feasibility, Economic Evaluation
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis …
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis C virus (HCV) and identifies strategies to achieve World Health Organization (WHO) elimination goals by 2030. Employing a microsimulation model spanning 2015 to 2050, the analysis assesses HCV epidemic trends, prevalence, mortality, and total care costs under various scenarios. Results show that between 2018 and 2022, over 7 million people were screened and 60,000 treated, projecting Rwanda's potential achievement of…
Health/Medicine | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Sub-Saharan Africa -
ArticlePublication 2024Disparities in TB Incidence by Race & Ethnicity Among the U.S.-Born Population in the U.S., 2011 to 2021
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born …
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born individuals from 2011 to 2021. Using national TB registry data, time-series analysis was conducted, stratifying by race/ethnicity and adjusting for age, year, and state of residence. Results indicate persistent disparities, with incidence rate ratios as high as 14.2 for American Indian or Alaska Native (AI/AN) females compared to non-Hispanic White individuals. Relative disparities were more pronounced for females, younger individuals,…
Health/Medicine | Infectious Diseases | Chronic Disease/Risk | North America -
ArticlePublication 2024Hypertension Care Cascades and Reducing Inequities in Cardiovascular Disease in LMIC
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries …
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries (LMICs) across wealth quintiles. Using individual-level data from nationally representative surveys in 44 LMICs, the researchers simulated improvements in the hypertension care cascade and assessed the distributional benefits. They raised diagnosis and treatment levels for all wealth quintiles to match the best-performing country quintile and estimated the resulting change in 10-year cardiovascular disease (CVD) risk. Results indicate greater health benefits…
Health/Medicine | Cost-Effectiveness Analysis | Chronic Disease/Risk